Worth reading
61In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
19
¥ million (acquisition price)Wording
Conditional
How definitive the wording is.This transaction
Acquisition of shares and conversion into a subsidiaryCounterparty入江喬介
Disclosing companyYAMASHITA HEALTH CARE HOLDINGS,INC.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.15 days from 決議 to 実行.White points represent dates designated as scheduled dates in the document.
Target company
・医用超音波に関する受託研究、開発 ・超音波を用いた医療用機器、周辺機器の開発および販売 ・コンサルティング（医用超音波関連）
Location Kokubunji, TokyoShare capital ¥30 millionDate of incorporation June 2000
Net Sales37百万円（2023年3月期）
Operating profit△39百万円（2023年3月期）
Net income for the current fiscal year△38百万円（2023年3月期）
Net assets2百万円（2023年3月期）
Consideration and expenses
Acquisition price¥19 million
Impact on Business Performance
Immaterial
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares and conversion into a subsidiary |
| Counterparty name | 入江喬介 |
| Name of the Subject Company | Microsonic Corporation |
| Business Description of the Subject Company | ・医用超音波に関する受託研究、開発 ・超音波を用いた医療用機器、周辺機器の開発および販売 ・コンサルティング（医用超音波関連） |
| Location of the Subject Company | Kokubunji, Tokyo |
| Capital Stock of the Subject Company | ¥30 million |
| Date of Establishment of the Subject Company | June 2000 |
| Net Sales of the Subject Company | 37百万円（2023年3月期） |
| Operating Profit of the Subject Company | △39百万円（2023年3月期） |
| Net Income of the Subject Company | △38百万円（2023年3月期） |
| Net Assets of the Subject Company | 2百万円（2023年3月期） |
| Acquisition price | ¥19 million |
| Number of shares acquired | 600 shares (600 voting rights) |
| Voting rights ownership percentage | Before 36.8％ → after 100％ |
| Impact on Business Performance | Immaterial |
| Date of board resolution | 2024年5月30日 |
| Contract Date | 2024年5月31日（予定） |
| Execution Date / Effective Date | 2024年6月14日（予定） |
Items this document does not state (14)
Expenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.マイクロソニックが独自の超音波技術・知財を有し、乳がん検査デバイスの開発を進めているため、その技術を取り込んで製造・販売分野の事業展開を加速し、グループ各社とのシナジー、事業領域の拡大、グループ機能の強化を図るとしている。一方、対象会社は直近3期連続で営業赤字・当期純赤字となっている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.